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Bioactive patcha b s t r a c t
Objective: To evaluate the regenerative capacity of non-supplemented and bioactive patchesmade of decel-
lularized porcine cardiac extracellular matrix (pcECM) and characterize the biological key factors
involved in possible cardiac function (CF) restoration following acute and 8 weeks chronic MI.
Background: pcECM is a key natural biomaterial that can affect cardiac regeneration following myocardial
infarction (MI), through mechanisms, which are still not clearly understood.
Methods: Wistar rats underwent MI and received pcECM patch (pcECM-P) treatment in either acute or
chronic inflammatory phases. Treated, sham operated (no MI), and control (MI without treatment) ani-
mals, were compared through echocardiography, hemodynamics, pathological evaluation and analyses
of various mRNA and protein level markers.
Results: Our results show that in both acute and long-term chronic MI models, pcECM promotes sig-
nificant cardiac function improvement, which is correlated to progenitor (GATA4+, c-kit+) and myocyte
(MYLC+, TRPI+) recruitment. Interestingly, recruited progenitors, isolated using laser capture microdis-
section (LCM), expressed both early and late cardiomyocyte (CM) differentiation markers, suggesting
differentiation towards the CM lineage. Recruited CM-like cells organized in a partially striated and
immature muscle fiber arrangement that presented connexin43 —a crucial mediator of cardiac electrical
conductivity. Concomitantly, pcECM was rapidly vascularized, and induced a constructive remodeling
process as indicated by increased M2/M1 macrophage phenotypic ratio and pathological evaluation.
Conclusions: Acellular pcECM patch implants alone, i.e., without added biologics, are bioactive, and
exert potent efficacy, stimulating biological regenerative processes that cooperatively lead to a cardiac
progenitor-based restoration of function, even after scar tissue had already formed.
Statement of Significance
MI (‘heart attack’) remains the leading cause of heart failure and death in developed-countries.
Restoration of cardiac function requires active turnover of damaged heart contracting cells (CM), how-
ever, CM endogenous regeneration is not efficient and is a matter of controversy. We show that a bioac-
tive biomaterial alone—decellularized heart tissue (pcECM)—without added cells or growth factors, can
elicit a complex regenerative response even after irreversible scarring. The pcECM patch induces
macrophage polarization towards constructive remodeling and cardiomyocyte progenitor cell
(GATA4+, c-kit+) recruitment (evidenced at both mRNA and protein levels) resulting in de novoInstitute
639798,
210 U. Sarig et al. / Acta Biomaterialia 44 (2016) 209–220immature striated-like muscle patterns (MLC+, TrpI+, connexin43+). We, therefore, suggest this bioactive
pcECM can model cardiac regeneration, and serve as a candidate for fast-track clinical application.
 2016 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The ideal therapy for myocardial infarction (MI) needs to bio-
logically stimulate and induce regeneration, address cardiac
mechanics, and consider the inflammatory stage of infarct scarring
during intervention. Biomaterials, of synthetic (e.g., PU, PLGA) and
natural (e.g., alginate, collagen, fibrin) origin, in either a patch or
injectable treatment modality, are widely suggested treatments
for the infarcted myocardium, each having its own pros and cons
as comprehensively reviewed elsewhere [1–3]. Typically,
biomaterial-treatments provide passive physical support to the
infarcted ventricle, preventing further deterioration according to
the modified law of Laplace [4]. Biological stimulation, however,
is essential for restoration of cardiac function (CF), and is mediated
by either bioactive factors incorporation into the biomaterials, and/
or through other intrinsic bio-inductive scaffold characteristics.
While biologics incorporation, e.g., cells, progenitor recruiting
cytokines and growth factors [2,5,6], has been previously sug-
gested for MI treatment, several major hurdles inhibit progress in
the experimental and regulatory route to effective translation of
this approach. As tissue repair mechanisms remain complex and
are not yet fully known, defining the optimal composition, sources
and desirable release profiles of the biologics needed to reach an
ideal regenerative response remains challenging. Second, with
each biologic agent affecting a spectrum of biochemical pathways,
the implications of any such myriad combination is difficult to pre-
dict, and can be expected to increase the burden and complexity of
the associated regulation. Alternatively, a promising class of intrin-
sically bio-inductive biomaterials is decellularized extracellular
matrices (ECM), whose major advantage lies in their high bioactiv-
ity i.e., their ability to stimulate cell recruitment, attachment, sur-
vival, proliferation, migration, and differentiation [7]. Moreover,
ECM’s reciprocal cross-talk with its resident cells can affect numer-
ous regenerative and reparative processes [8,9].
In cardiac therapy, ECMs of non-myocardial tissues were previ-
ously suggested as adequate biomaterials for cardiac augmentation
[10–13]; however, as ECM differ from one tissue to another, they
may intrinsically lack the optimal composition, ultrastructure,
biomechanical and biochemical cues that constitute a prerequisite
for myocardial-specific support and regeneration [3,14,15]. Several
myocardial ECM scaffolds were isolated from rat [16,17], porcine
[18–22] and human [23,24] origin. In particular, porcine cardiac
derived ECM (pcECM) displayed promising cell support ability
[20,25], myocardial matching mechanical properties [20,22,26],
and human equivalent composition [20,22]. In addition, pcECM
availability and reproducibility can be assured through stringent
quality control, suggesting xenograft clinical relevancy
[2,16,18,22,24]. Nevertheless, the ability of pcECM to induce a
myocardial reparative process and its possible biological mediators
remain largely unknown, especially in chronic MI models, which
are characterized by the presence of a mature and irreversible scar
tissue prior to treatment administration.
Accordingly, we hypothesize that natural, bioactive and non-
supplemented acellular pcECM patches (pcECM-P) can improve CF,
even after scarring, and increase contractility through biological
mechanism of action. The role of pcECM-P in restoration of CF was
studied herein in both acute and chronic MI models, i.e., before
and after scar tissue formation, respectively. Cardiac energetics,
dimensional, and functional parameters were monitored throughechocardiography and hemodynamics. By implanting acellular
pcECM-P, we were able to explant and study the involvement of
various recruited cell types, including progenitors, at the mRNA
and protein level expression of various cardiac, vascular, and
innate immunity markers. Based on our experimental data we sug-
gest a biological, model-independent mechanism that explains the
potent pcECM-P efficacy reported herein. We further suggest that a
pcECM patch treatment can provide an important platform for
mechanistic studies of ECM bioactivity and a good candidate for
future fast-track clinical applications.2. Materials and methods
2.1. Experimental design
All procedures and animal handling were approved and per-
formed in accordance to Institutional Animal Care and Use Com-
mittee (IACUC) guidelines, National University of Singapore. A
total of 88 male Wistar Rats (300–350 g), were randomly divided
into eleven groups defined by their sacrifice time point and their
treatment modality (n = 8 rats per group and time point, Supple-
mentary Table S1). Two MI models were studied – an acute model,
in which treatment was given immediately after MI induction; and
a chronic model, in which two surgeries were performed—the first
for MI induction and the second, 30 days afterwards, for treatment.
For all experiments, pcECM matrices were randomly distributed
between groups. Each model had its own control and sham opera-
tion groups (positive control) as indicated in Supplementary
Table S1. All controls underwent MI and suturing similarly to patch
attachment just without the pcECM to rule out possible recovery
effect due to stunned myocardium. All animals were monitored
by echocardiography throughout the experimental timeline; at
end-points, evaluation was through invasive hemodynamic assess-
ment and a thorough double-blinded pathological investigation.
For isolation of recruited cells’ mRNA, five additional rats were
treated with pcECM-P in an acute model and allocated for careful
patch isolation using laser capture microdissection (LCM), 30 days
post implantation. The extracted mRNA was studied by qPCR for
the expression of 14 representative CM early and late developmen-
tal markers, and compared to neonatal rat CM and mature rat heart
samples as controls. To better understand the organization and
contribution of particular recruited cell population subsets at the
protein level, selected markers of cardiac, vascular and innate
immunity were visualized, quantified, and studied for their possi-
ble correlation to functional improvements using immunohisto-
chemistry (IHC) and immunofluorescent (IF) stains.2.2. Implant preparation
Acellular pcECM (1.5 cm diameter, 1.5 mm thick) patches were
produced and disinfected as previously published [20]. Briefly,
female pig (40–70Kg) hearts were harvested in cold sterile PBS
containing 200U/ml penicillin, 0.2 mg/ml streptomycin (Pen-
Strep, Biological Industries) and 2 lg/ml amphotericin B (Fungi-
zone, Gibco). Left ventricles were isolated and horizontally cut
in three. The two larger rings were further cut longitudinally into
3–4 parts, which were sliced parallel to the epicardial plain into
3 mm thick sections. The myocardial tissue sections were
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Sigma) and hypotonic (0.7% NaCl – 0.02% EDTA) solutions for two
hours each, followed by immersion in 0.05% Trypsin (Sigma) –
0.02% EDTA in PBS at pH 7.4 and 37 C (supplemented with Pen-
Strep and Fungizone) for two 24 h cycles. Finally, treated slices
were agitated in a fresh detergent solution of 1% Triton-X-100
(Ethylene glycol octyl phenyl ether) and 0.1% ammonium hydrox-
ide in PBS for four consecutive 48 h cycles, and extensively washed
in DDW to remove any detergent remains. Effective decellulariza-
tion was evaluated by whitening of the patch material and verified
by picogreen DNA quantification as well as histological cross sec-
tional stains for Masson trichrome and H&E (data not shown). Prior
to implantation, 70%(v/v) ethanol disinfected patches were washed
with PBS containing double antibiotic concentration (Pen-Strep
and Fungizone), followed by immersion in standard culture media
(standard aMEM, Biological Industries with antibiotics but without
serum) for 1–2 h at 37 C and in 5% CO2.
2.3. Induction of MI and pcECM treatment
Male Wistar rats were anesthetized using a 3–5% isoflurane/
oxygen mixture, intubated and mechanically ventilated (Inspira
ASV ventilator, Harvard Apparatus, Holliston, MA). The heart was
exposed by left thoracotomy and pericardiectomy via the 5th inter-
costal space. The left anterior descending (LAD) coronary artery
was ligated proximally using a 7–0 Premilene suture (B. Braun,
Aesculap, Tuttlingen, Germany). Infarction was confirmed by visi-
ble blanching of the left ventricle (LV) and significant ECG changes.
pcECM-Ps were sutured (7/0 absorbable glyconate suture, Mono-
sync, B. Braun) onto the infarcted area either immediately (acute)
or 30 days (chronic) post MI, as indicated. To assess the suturing
effect, additional n = 8 rats received patch gluing without sutures
(TISSEEL fibrin sealant, Baxter, UK; Supplementary Fig. S1) and
were monitored through echocardiography for 30 days. Control
animals did not receive any treatment after MI induction, apart
from sham sutures to rule out stunned myocardial recovery; while
sham group animals underwent only thoracotomy and pericardiec-
tomy. Following chest closure in layers and extubation, animals
were transferred to an intensive care unit for recovery and received
subcutaneous administration of Enrofloxacin (25 mg/kg) and
Buprenorphine (0.05 mg/kg) for up to 5 days.
2.4. Echocardiography
Transthoracic echocardiography was performed under general
anesthesia before MI induction (i.e., baseline reads) and at speci-
fied time points postoperatively, using the Vivid S6 ultrasound sys-
tem (General Electric VingMed, Horton, Norway) equipped with a
i12L-RS linear array transducer (5–13 MHz). Acquired B- (Bright-
ness, 2D) and M- (Motion) mode images and data were analyzed
by EchoPacTM software (Version 6.0, General Electric Vingmed, Hor-
ten, Norway). Functional parameters monitored were ejection frac-
tion (%EF), fractional area change (%FAC) and fractional shortening
(%FS). Dimensional parameters monitored were: left ventricle inte-
rior diameter in diastole and systole (LVIDd and LVIDs, respec-
tively), inter-ventricular septum dimension in diastole and
systole (IVSd and IVSs, respectively) and left ventricle posterior
wall dimension in diastole and systole (LVPWd and LVPWs, respec-
tively). Relative infarct size was determined only at diastole (to
minimize measurement error) as the percentage of the akinetic
region to the entire left ventricular circumference, averaged from
three consecutive samples at the papillary muscle level in the short
axis view, based on a previously published methodology [27,28].
All other formulas used for calculations of echocardiographic data
were as previously established [29] and detailed in Supplementary
Table S2. To avoid random block effect in any particular parametermonitored, all dimensional data results presented are an aver-
age ± SD of paired baseline normalized values. That is, for each
rat the 30 days post pcECM-P implantation dimensional value
was normalized to its own baseline value (measured prior to
infarction for LVID, LVPW and IVS; or 3 days post infarction for
Infarct size and the normalized values were averaged per group.
2.5. Hemodynamic analysis
Hemodynamic assessments were performed immediately prior
to sacrifice as previously published [30]. Briefly, following median
sternotomy, a 2 mm transit-time flow probe (Transonic Systems,
Ithaca, NY, USA) was placed around the ascending aorta for cardiac
output measurement used for volume calibration (a calibration). A
pressure–volume (P-V) catheter (SPR-838 NR, Millar Instruments,
Houston, TX) was inserted into the left ventricle for left ventricular
pressure–volume relation studies, using the MPVS-Ultra system
(Millar Instruments, Houston, TX) and PowerLab 16/30 (AD Instru-
ments, Mountain View, CA). Volume calibration was performed
using the 910–1048 vol Calibration Cuvette (2–15 mm wells) (AD
Instruments, Mountain View, CA), according to the manufacturer’s
instructions. A saline calibration (50–100 ll of 30% w/v NaCl in
DDW) was used to determine parallel volume (Vp).
Cardiac dimensional and functional characteristic parameters
were obtained from analyses and calculations using LabchartProTM
software (AD Instruments, Mountain View, CA) of at least five con-
secutive cardiac cycles within baseline normal recordings. These
included maximal and mean pressures per cycle (Pmax and Pmean,
respectively), end diastolic/systolic pressures and volumes (EDP,
ESP and EDV, ESV, respectively), cardiac output [CO =
(EDV  ESV)*heart rate], stroke work (SW, area blocked within
the P-V loop), maximal slopes of systolic and diastolic pressure
(+dP/dtmax and dP/dtmin), time constants of LV pressure decay
(Tau) and the average -dp/dt during the diastole isovolumetric
relaxation periods (IRP average dp/dt).
Inferior vena cava occlusion tests were performed to assess pre-
load independent LV parameters: maximal ventricular elastance
(Ees/max, measured as the slope of the ESP volume relationship lin-
ear curve, ESPVR); slope of the EDP volume relationship (EDPVR)
linear curve; preload recruitable stroke work (PRSW, measured
as the slope of the SW to ESV linear fitting curve); pressure volume
area (PVA), which marks the blocked area between the EDPVR, the
ESPVR and the systolic curve of the PV loop under normal condi-
tions at the beginning of the occlusion test (equals the total energy
generated by the ventricular contraction), and cardiac efficiency
(defined as the ratio of SW/PVA). Representative PV loops of base-
line and occlusion tests for normal (sham) hearts, MI controls and
pcECM-P treated hearts in acute and chronic models are presented
in Supplementary Fig. S2.
2.6. Histopathological assessment
Following hemodynamic recordings, animals were euthanized.
Necropsies were performed on three randomly selected animals
from each treatment group. During necropsy, major organs (lungs,
liver, spleen, brain, kidneys, tracheal and bronchial lymph nodes)
were extracted and pathologically inspected for gross pathological
findings, followed by organ fixation in neutral buffered formalin
(NBF, 10%v/v, Sigma, St. Louis, MO) at room temperature. For car-
diac assessment, all hearts were transversely cut in the middle of
both ventricles through the infarct zone (with/without the patch)
in the LV. Both sections were processed to paraffin blocks, sec-
tioned (5 lm, Leica RM2255/ RM2235 Microtome, Germany) and
stained with hematoxylin and eosin (H&E, Richard-Allan Scien-
tificTM, Thermo Scientific, MA). A double-blinded evaluation and
lesion scoring of histopathology slides were performed (on at least
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nary pathologist (MAH). Scoring was performed using quantitative
criteria for features of inflammatory and tissue remodeling
response after implantation of decellularized scaffold materials,
as previously described [31], and detailed in Supplementary
Table S3. Higher scores are indicative of a constructive remodeling
response whereas low scores are indicative of scar tissue or foreign
body type response. Following blinded scoring, animal attribution
was revealed to enable concluding pathological remarks per group.
Sequential sections were also stained by Masson’s trichrome (MTC)
as previously published [32] to evaluate patch and infarct loca-
tions, morphology and dimensions (identified by the blue color
staining).
2.7. LCM, mRNA isolation and analyses
Randomly assigned hearts (n = 5 hearts) were harvested
30 days post implantation of pcECM-P in an acute model. Hearts
were quickly rinsed in PBS, snap-frozen in liquid nitrogen, and
stored at 80 C until sectioning. Ten lm cross-sections (without
OCT embedding) were cut (Leica CS5030 cryostat, Germany) and
mounted on PEN membrane slides (Life Technologies, CA). LCM
of patch areas only (Arcturus LCM, Life Technologies, CA) was per-
formed according to the manufacturer’s instructions using Cap-
Sure Macro Caps (Life Technologies, CA). Patch areas were
manually determined, leaving a safe distance from the infarct-
patch interface, and the dissected areas were imaged prior to and
following dissection to ensure no contaminating mRNA from the
infarct or heart were accidentally collected. RNA was extracted
separately from each heart sections’ pool (at least 4 patch sections
per sample) using the PicoPure RNA isolation kit (Life Technolo-
gies, CA). Neonatal rat CM (Lonza, Switzerland) and native heart
tissue (nP 3 for each sample type) were processed for mRNA iso-
lation using QIAzol Lysis reagent and miRNeasy mini Kit (Qiagen,
Netherlands). All mRNA samples were subsequently evaluated by
qPCR (BioRad CFX96 analyzer, BioRad, CA) with custom designed
(Supplementary Table S4) short amplicons (70–80 bp) using the
Exiqon LNATM system (Exiqon, Denmark) and relevant syber-green
based amplification reagents (ScienceWerke, Singapore). All data
pre-processing and analyses were performed using GenEx
6.0.3.415 (MultiD, Sweden) for interplate calibration, data valida-
tion, automatic imputation housekeeping gene normalization,
technical replicates averaging (n = 3 technical run per biological
replica), logarithmic transformation, autoscaling and analyses.
The analyses included principal components analyses (PCA), and
Ward’s method clustering based on absolute Pearson’s correlation
for genes and samples (generating gene expression relative ‘heat
maps’).
2.8. Immunohistochemical (IHC) and immunofluorescent (IF)
assessments
IHC staining was performed using several primary antibodies
evaluating various aspects of pcECM bio-activity, integration and
compatibility. Primary antibodies used: rabbit anti-rat GATA4,
MYLC, c-kit, connexin43, von-willebrand factor (vWF) and CCR7
(Abcam, Cambridge, UK); rabbit anti-rat CD31; goat anti-rat
CD206 (Santacruz Biotechnology, Dallas, TX) and vimentin (Milli-
pore); and mouse anti-rat a-smooth muscle actin (a-SMA, Cell-
Marque, Rocklin, CA), MYLC and Troponin I (Abcam, UK). IHC stains
were performed automatically according to the manufacturer’s
instructions (Leica BondTM autostainers, Leica Microsystems, Ger-
many). Immunofluorescet (IF) stains were manually performed.
Each section was pre-treated with Image-iTTM FX (Life Technolo-
gies) signal enhancer for 30 min at room temperature, blocked
with 5% donkey serum and stained with sequential (1st pri-mary? 1st secondary? 2nd primary? 2nd secondary) antibody
incubations at room temperature. All antibody dilutions and wash-
ing (3 washes after each incubation step) were in blocking solution
comprising 5% donkey serum. Primary antibodies were incubated
for 60 min and secondary antibodies—for 30 min, followed by DAPI
counter staining (NucBlue, Life Technologies), mounting (Immu-
MountTM, Thermo Scientific) and nail-polish sealing. Image acquisi-
tion was performed using a Nikon eclipse TE2000 inverted micro-
scope. Supplementary Table S5 summarizes the appropriate
dilutions and staining conditions for both IHC and IF.
2.9. Image analyses and quantifications
Histological and IHC stains’ image analyses were performed by
manual annotation of at least seven random squares (minimum
0.2 mm2 per square) in distinct regions of patch, infarct and their
interface. Positive cells and blood vessel quantity were indepen-
dently and blindly counted by three persons and normalized to
surface area. Representative pictures of at least three technical
repeated sections for each animal (nP 3 animals that were IHC
analyzed per group per time point and antibody staining) are
presented.
2.10. Statistical analyses
Sample size was a priori determined based on a statistical
power of 95% (for k = 3 sample means), at conventional a = 0.05,
as evaluated from previously published data of similar acute rat
models [33]. Outliers, if present, were excluded based on the
mahalanobis D2 method. All results were found to be normally dis-
tributed according to the Shapiro-Wilk goodness of fit W test.
Results are expressed as the mean ± standard deviation of each
group. Statistical significance was evaluated by one-way analyses
of variance (ANOVA) and Tukey’s HSD test for multiple compar-
isons at individual time-point experiments, and by two-way
ANOVA with post hoc corrections for time and model comparisons
when applicable, using JMP 6.0 statistical software (SASTM, Cary,
NC). For all comparisons, p < 0.05 was considered significant. Assay
specific sample size and additional statistical analyses methods are
mentioned in the relevant methodology sections of the supple-
mental online data.
For comparison purposes, unless otherwise stated, data are pre-
sented for the 30-day time-points post implantation, i.e., 30 and
60 days post MI for the acute and chronic models, respectively,
accompanied by a corresponding control group.3. Results
Initial infarction size was similar between groups (26 ± 9%, Sup-
plementary Fig. S3).
3.1. Echocardiographic assessment
Significant improvements of the left ventricle (LV) systolic and
diastolic dimensions were observed 30 days post treatment
(Fig. 1). In both models, pcECM-P significantly reduced the normal-
ized infarct size, and left ventricular internal diameter (LVID),
while increasing the left ventricular posterior wall thickness
(LVWP) towards the sham values. The systolic thickness of the
inter-ventricular septum (IVS)—signifying the compensatory
response of the healthy myocardium to infarction—in the treated
groups was similar to the sham and significantly higher than the
control in both models. In general, apart from relative infarct size
(quantified only in diastole), all other parameters exhibited higher
change-amplitude in systole compared to diastole.
Fig. 1. Echocardiography evaluation of cardiac dimensions 30 days post treatment
for acute and chronic models (left and right panels, respectively). Relative infarct
size (A, normalized to the value at 3 days post infarction), LV internal diameter
(LVID), LV posterior wall thickness (LVPW), and inter-ventricular septum thickness
(IVS) (B-D, respectively, normalized to baseline values). Dark gray—pcECM-treated
group; Light gray—control; white—sham. ⁄Statistical significance indicator
(p < 0.05). Results represent the mean ± SD of each group as indicated in Supple-
mentary Table S1.
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ments (p < 0.001) were observed in fractional area change (FAC),
ejection fraction (EF) and fractional shortening (FS) towards the
‘normal’ sham values, when compared to the non-treated controls
(Fig. 2). In the acute model, the average FAC at 60 days post treat-
ment was even similar to the sham group value (Fig. 2A). Similar
observations were obtained for patches glued on top of the infarcts
(instead of sutures, Supplementary Fig. S1), demonstrating patch
efficacy that is independent of the implantation method.
3.2. Hemodynamic assessment
Under normal baseline recordings, pcECM-P treated hearts in
both models graphically displayed P-V loops, which approxi-
mated sham appearance (Supplementary Fig. S2), as also reflected
in significantly higher generated pressures and cardiac outputs
(Supplementary Table S6). Furthermore, the patch-treated groups
displayed restoration in most baseline parameters (Fig. 3A-E to
levels similar to the sham group (p > 0.05).
Preload independent hemodynamic measurements taken
during occlusion tests (Fig. 3F–H) provided similar findings in
both models. The differences between treatment and control
groups were graphically apparent by the slope of the end systolic
pressure volume relationship (ESPVR) curve (Supplementary
Fig. S2)—representing the maximal cardiac elastance (Ees, Fig. 3F).
Parallel significant salvage was observed in terms of heart
efficiency, and preload recruitable stroke work (PRSW, Fig. 3G-H,
respectively) for both acute and chronic models.
3.3. Pathological evaluation
Patches remained attached to treated hearts, and were mildly
degraded (still largely intact even 60 days post implantation), with
lack of connective-tissue disruption, slight to no-encapsulation,
and no apparent multinucleated giant cells (Fig. 4). Similar levels
of infiltrating cells appeared in the patch–infarct interface and
within the core of the patch, in both models.
Pathological scoring indicated the pcECM biocompatibility and
its induction of a constructive remodeling process (Supplementary
Table S3), based on previously established criteria [31]. Macro-
phage quantification of the M2/M1 ratio in the acute model,
revealed a time-dependent increase up to 60 days post implanta-
tion (Fig. 5). Similar ratios were measured in both models, 30 days
post treatment (Fig. 5C), which were also comparable to their
equivalent untreated control values (1.2 ± 0.6, p > 0.05, data not
shown).
CD31, vWF and a-SMA stains were used to evaluate the mean
vessel density (MVD) in both infarct and patch areas. MVD levels
within the infarcts of both treated and control groups remained
the same for all time-points in both models (p > 0.05, 65 ± 35
vessels/mm2, data not shown). In comparison, MVDs within the
pcECM-Ps were significantly higher 14 days post treatment
and gradually decreased over time, being still significant at 30 days
and reaching values that are similar to baseline at 60 days (Fig. 6).
The vascularity of the pcECM-P in both models, 30 days post
implantation, was similar (p > 0.05) and appeared to be denser
closer to the interface with the host.
3.4. Recruitment of cardiac progenitor and muscle cells
pcECM-Ps were carefully isolated from the explanted infarcted
ventricles of the acute model 30 days post implantation using
LCM (Fig. 7A). Principal component analyses (PCA) positioned the
mRNA expression profile of pcECM-P-recruited cells between that
of rat neonatal CM (NRCM) and mature rat heart (MRH, Fig. 7B,
‘scores’). All cardiomyocyte markers studied were positivelyexpressed within the isolated pcECM-P samples, and were gener-
ally clustered into two groups indicating the major contributors
to the progenitor/neonatal vs. the mature states (Fig. 7B ‘loadings’).
These findings were also confirmed by independent heat-map
clustering (Fig. 7C).
Representative ‘progenitor’ (GATA4 and c-kit (KIT)) and
‘mature’ (MYLC and TrpI) markers were further evaluated at the
protein level (Fig. 8A-B). Image analysis quantification (Fig. 8C-F)
revealed that only GATA4+ and MYLC+ cell densities significantly
increased through time (Fig. 8C-D, respectively) displaying linear
penetration rates (R2 > 0.95, Supplementary Fig. S4). The ratio
between GATA4+/MYLC+ cells, however, declined logarithmically
over time, stabilizing at a 5:1 ratio beyond the 30-day
Fig. 2. Echocardiographic evaluation of CF and it correlation to progenitor and muscle cell recruitment. Fractional area change (FAC), ejection fraction (EF) and fractional
shortening (FS) kinetics in acute (A–C, respectively) and chronic (D–F, respectively) models. Symbols: Open squares—sham; circles—pcECM-P treated group; closed squares—
control. Arrows indicate the treatment time-point. Results represent the mean ± SD of each group and time point as indicated in Supplementary Table S1.
Fig. 3. Hemodynamic evaluation of cardiac function and contractility 30 days post treatment. Parameters measured under physiological normal conditions: Peak rate of
pressure rise (dp/dtmax, A), average pressure decline during isovolumetric relaxation period (IRP average dp/dt, B), peak rate of pressure decline (dp/dtmin, C), and Stroke
work (SW, D). Parameters measured during occlusion tests: Cardiac end systolic elastance (Ees, E), cardiac efficiency (F), preload recruitable stroke work (PRSW, G) and
relaxation time constant calculated byWeiss method (Tau, H). Dark gray—pcECM treated group; light gray—control; white—sham. ⁄Statistical significance indicator (p < 0.05).
Results represent the mean ± SD of each group as indicated in Supplementary Table S1.
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c-kit+ (Fig. 8E), total (Fig. 8F) or TrpI+ (data not shown) cells. More-
over, quantified GATA4+ and MYLC+ cell densities within the patch
were highly correlated to FS as a representative functional param-eter (R2 = 0.888 and 0.635, respectively) (Fig. 8C and Fig. 8D,
respectively). No correlation to functional improvement was
observed, however, in the case of c-kit+ (Fig. 8E), total cell quanti-
ties (Fig. 8F) or TrpI+ cells (data not shown).
Fig. 4. PcECM-P implantation and microscopic evaluation. pcECM-P is soaked in normal culture media (A, left) and sutured onto infarcted rat heart (A, right). Representative
gross pictures of explanted pcECM-P treated hearts 30 days post implantation in acute (B) and chronic (C) models are shown next to their respective controls, as indicated;
arrows point to patch area. Vertical black lines (B and C, left) mark the cutting planes on ventral and dorsal views to enable the proximal and distal cross sectional views on
the right. Representative overview images of left ventricular (LV) Masson’s Tri-Chrome (MTC) stains for patch treated hearts 30 days post implantation in acute and chronic
models next to their respective non-treated MI controls (D). Higher magnifications of MTC (left) and Hematoxylin and Eosin (H&E, right) stains in both acute (E) and chronic
(F) models. Scale bars: (A, right)–5 mm; (D)–1 mm; (E  F)–100 lm.
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incomplete de novo fiber-like morphology of CM-like (MYLC+) cells
ensheathed by fibroblastic cells (Vimentin+, Fig. 8G). In some cases,
partially striated muscle-like fibers appeared to form within the
patch (Supplementary Fig. S5). GATA4 and the cardiac specific
gap–junctional protein—Connexin43—were co-localized within
the MYLC+ cells recruited to the patch. However, while c-kit was
readily visualized within some cells at the patch area, not all
c-kit+ cells were co-localized with GATA4 (Fig. 8G).
4. Discussion
Most studies to date, utilized myocardial ECM for cardiac repair
in its injectable form—produced through harsh ECM grinding, andacidic and enzymatic digestion—suggesting its possible biological
activity, through mechanisms, which are still not clearly under-
stood [18]. This limited mechanistic understanding may result
from the complexity in pinpointing the injectable ECM role in the
remodeling process as, unlike the patch, it cannot be easily
retrieved from the infarcted tissue. pcECM patches, on the other
hand, preserve their original, unaltered and bioactive natural mor-
phology and composition, while displaying superior ventricular
mechanical support.
Our results clearly indicate that pcECM-P is able to not only pre-
vent further deterioration in both acute and chronic MI models, but
also improve contractility, ventricular dimensions and cardiac
remodeling. In particular, FAC, ESPVR slope (Ees), dp/dtmax and car-
diac efficiency even achieved normal-like values with time. As
Fig. 5. pcECM-P induces favorable macrophage polarization. M2 and M1 represen-
tative IHC stains for acute (A) and chronic (B) models 30 days post treatment. M2/
M1 ratio quantification (mean ± SD of n = 6 animals per time point) for 14, 30 and
60 (acute) and 30 (chronic) days post treatment (C). ⁄Statistical significance
indicator (p < 0.05). Scale bars: 50 lm.
Fig. 6. pcECM-P vascularization. Representative IHC CD31 + vWF and a-SMA stains
for blood vessels endothelium and smooth muscle cell, respectively, within the
pcECM-P explants of acute (A) and chronic (B) MI models 30 days post treatment.
Mean vessel density (MVD) quantifications (mean ± SD of n = 6 animals per time
point) for 14, 30 and 60 (acute) and 30 (chronic) days post treatment (B). Scale bars:
50 lm. ⁄Statistical significance indicator (p < 0.05).
216 U. Sarig et al. / Acta Biomaterialia 44 (2016) 209–220results are model-independent, we conclude that pcECM-P efficacy
involves, beyond the established mechanical support, an active
biological mechanism, which is at least partly mediated at the cel-
lular level by recruited progenitors that differentiate to CM-like
cells and restore CF.
Chemoattraction to ECM natural degradation byproducts, ter-
med ‘matrikines’ or ‘bioactive matricryptic peptides’, constitute a
generally accepted mechanism of ECM bioactivity—inducing
inflammation, angiogenesis, wound healing and regeneration
[34,35]. The ability of decellularized ECM to induce a host regener-
ative response, according to this general mechanism, is dependenton the recruitment of tissue specific progenitor cells, as previously
demonstrated, albeit for non-cardiac derived ECMs and other dis-
ease models [31,36,37]. Bioactive matrikine release occurs by var-
ious ECM remodeling enzymes (e.g., MMPs [38]), such as secreted
by macrophages and fibroblasts. Such enzyme expression was pre-
viously also reported for our pcECM [20].
In particular, the major role of macrophages in both infarct
healing [39] and ECM degradation and remodeling was highlighted
[31,37]. It was suggested that early induction of an M2macrophage
‘regulatory’ phenotype versus an M1 ‘activated’ phenotype and
Fig. 7. Expression of cardiomyocyte (CM) progenitor and maturation markers in pcECM-P recruited host cells. Representative images (out of n = 5 animals) of patch cross-
sectional regions are shown prior to and following LCM (A). Patch margins are larger when nearing the infarct border zone to avoid ‘contaminating’ mRNA from the
infarct/heart tissue. PCA showing the sample ‘scores’ and gene ‘loadings’ 30 days post implantation (B). PcECM-P recruited cells are compared to two positive control groups:
Rat neonatal CM (RNCM) and mature rat heart (MRH) biopsies’. Small spheres indicate single sample scores (mean ± SD); bigger spheres indicate the average and standard
error for each sample group (B, left panel). ‘Progenitor’ (shaded in green) vs. ‘mature’ (shaded in blue) phenotype clusters are shown based on both relative PCA gene loadings
(B, right panel) and on independent Ward’s algorithm and absolute Pearson’s correlation analyses represented in log(2) auto-scaled expression ‘heat-map’ (C). While all genes
were positively expressed in all samples, their relative expression heat-map (low in green, and high in red) positions the pcECM-P samples in-between the average RNCM and
MRH phenotypes. Two genes in each cluster were chosen for subsequent analyses at the protein level (B, underlined and C, arrows). Scale bars: 500 lm.
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stances [31]. Quantification of M2 over M1 macrophage density
ratios within the patch increased by almost sixfold from day 14
to the day 60 time-point, indicating a constructive reaction kinetics
by the host immunity. Moreover, a similar ratio measured in both
the acute and chronic models 30 days post implantation validates
the assumption that the quantified effect is patch dependent and
not animal model related. Indeed, this ratio correlates well to
pathological scoring of a wide range of commercially available
ECM materials. High scores (9–13) reflected induction of a regen-
erative response and implant integration as opposed to lower
scores indicating scar tissue formation, encapsulation or rejection[31]. Based on double-blinded evaluation and using the same scale,
our pcECM-P yielded a score of 13 ± 1, portraying the pcECM as a
strong bioinducing material, as also supported by our mRNA and
protein level analyses.
mRNA analyses revealed that the recruited cell gene expression
showed intermediate profile between two major gene clusters—‘
neonatal/progenitor’ and ‘mature native heart tissue’—possibly
due to cell maturation process, yielding a ‘transitional’ gene
expression pattern 30 days post implantation. GATA4 and MYLC,
each belonging to a different cluster, were chosen as representative
markers for protein level analyses, displaying co-localization as
indicated by double positive cells. Both markers, but not others
Fig. 8. Recruited progenitor and muscle cell density increases through time as cells self-organize in muscle ‘fiber-like’ structures. Representative IHC stains for GATA4, c-kit,
MYLC, and TrpI expressed in explanted pcECM-Ps 30 days post implantation in acute (A) and chronic (B) models (brown, positive stains; blue, nuclei counterstaining). Image
analyses quantifications per time and model of positive cell densities for GATA4, MYLC and c-kit (C-E, Left, respectively; nP 3 animals per time-point and group), and their
respective linear regression correlation to functional improvement (FS, as representative; excluded outliers appear in red, C-E, Right). Total patch cell densities (F, Left) and
total cell counts’ lack of correlation (F, Right) are shown as control. Representative images (60x) of IF double stains (red and green as indicated), counter-stained with DAPI
(blue) and overlaid on the bright-field (gray) image of the ECM fibers of pcECM-Ps’ cross-section, 30 days post implantation (G). Co-expression is indicated by white arrows.
Scale bars: (A and B) – 100 lm. (G) – 10 lm.
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increase in infiltration, which correlated to improved ventricular
contractility. Particularly, the kinetic profile of their density ratio
within the patch suggests that GATA4 expression precedes that
of MYLC. Supporting this notion is the recent report showing that
GATA4 up-regulates the expression of cardiac specific MYLC [40].
We, therefore, suggest that a differentiation process, in which
GATA4+ cells start expressing CM-specific MYLC with increasing
frequency through time, occurs. This process highlights the impor-
tance of these two specific cell types/markers in a biological regen-
erative process transpiring following implantation.
GATA4 up-regulation was previously shown to enhance secre-
tion of paracrine factors (e.g., IGF), which extended survival and
contractility of neighboring CMs [41], endogenous cardiac stem
cells and early committed cells [5], hence suggesting GATA4 bio-
logically active role in cardiac regeneration. These mechanisms
are in line with our findings in which GATA4+ cell infiltration con-
tinues to rise throughout the experimental timeline and correlate
to functional improvement. Interestingly, documented GATA4
expression in untreated infarcted rat heart was shown to peak
two weeks after infarction and return to baseline levels after one
month [42]. Conversely, in our study, the measured density of
GATA4+ cells within the pcECM-P continued to rise without indica-
tion of plateauing, suggesting that the regenerative process was
still on-going even 60 days post implantation. Concomitantly, our
histological evaluation suggests that de novo self-assembled
‘muscle-like fibers’ are being formed, comprising CM-like cells
(MYLC+ cells, sometimes also partially striated), ensheathed with
supporting fibroblsats and forming gap–junctions (connexin43)
with neighboring cells. These recruited CM-like (MYLC+) cells
may directly contribute to improved localized regional contractil-
ity, as previously suggested for urinary bladder matrix (UBM) in
a cardiac muscle defect model [43]. A similar phenomenon was
also documented for skeletal muscle tissues treated with decellu-
larized matrix in a volumetric muscle loss model [44].5. Conclusions
Our results point to a complicated regenerative process initi-
ated and regulated by a cross-talk between pcECM, the host innate
immune system and the cardiac resident progenitor/satellite cells.
As an initial reaction, macrophages recognize pcECM as an accept-
able and biocompatible material. This recognition translates into a
constructive remodeling process in which angiogenesis likely
occurs—through canonical inflammation mechanisms. During this
process, some mild degradation of the pcECMmaterial attracts car-
diac progenitors such as GATA4+ cells. As long as the mild degrada-
tion process occurs, chemoattraction is retained, which may
explain the linear rate of progenitor cell infiltration throughout
the experimental time line evaluated. The infiltrated GATA4+ pro-
genitor cells biologically contribute through paracrine signaling—
improving CM salvage in the infarcted area. Subsequently, some
of the GATA4+ cells differentiated to (MYLC+), though the possibil-
ity of parallel recruitment of both cell types into the patch cannot
be entirely ruled out. These myocytes self-organize to muscle
‘fiber-like’ patterns, which are gap–junctional coupled in support
of the underlying infarcts. Of note is that this suggested mecha-
nism can regenerate and restore CF even after scar tissue has
already formed, which to the best of our knowledge, has not been
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